IL10 and myocardial infarction: Prior studies of overexpression of IL-10 in MSCs demonstrated enhanced MSC therapeutic efficacy in preclinical models of endotoxin-induced [13] and ischemia–reperfusion-induced [14] lung injury and following myocardial infarction [15].